What is Zacks Research's Forecast for MMSI FY2024 Earnings?

Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) - Zacks Research upped their FY2024 earnings per share (EPS) estimates for shares of Merit Medical Systems in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings of $3.36 per share for the year, up from their previous forecast of $3.31. The consensus estimate for Merit Medical Systems' current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems' Q3 2025 earnings at $0.93 EPS, Q4 2025 earnings at $0.98 EPS, FY2025 earnings at $3.70 EPS and FY2026 earnings at $4.07 EPS.

A number of other research analysts also recently commented on the company. Barrington Research restated an "outperform" rating and set a $114.00 price objective on shares of Merit Medical Systems in a research note on Thursday, October 31st. Needham & Company LLC reiterated a "buy" rating and set a $109.00 price target on shares of Merit Medical Systems in a research report on Thursday, October 31st. StockNews.com lowered Merit Medical Systems from a "buy" rating to a "hold" rating in a report on Sunday, November 3rd. Bank of America upped their price target on Merit Medical Systems from $92.00 to $103.00 and gave the company a "neutral" rating in a research report on Monday, September 16th. Finally, Wells Fargo & Company upped their price target on Merit Medical Systems from $85.00 to $103.00 and gave the company an "equal weight" rating in a research report on Monday, September 16th. Three equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Merit Medical Systems currently has an average rating of "Moderate Buy" and a consensus target price of $103.36.

Merit Medical Systems Stock Performance

Shares of NASDAQ MMSI traded up $0.07 during trading on Friday, reaching $105.10. The stock had a trading volume of 90,610 shares, compared to its average volume of 437,982. Merit Medical Systems has a one year low of $65.46 and a one year high of $106.87. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The stock has a market cap of $6.13 billion, a PE ratio of 51.49, a P/E/G ratio of 2.60 and a beta of 0.89. The firm's 50 day moving average price is $98.41 and its two-hundred day moving average price is $90.65.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The company had revenue of $339.85 million for the quarter, compared to analyst estimates of $334.60 million. During the same period in the prior year, the company posted $0.75 EPS. Merit Medical Systems's quarterly revenue was up 7.8% on a year-over-year basis.

Institutional Trading of Merit Medical Systems

Large investors have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System boosted its stake in Merit Medical Systems by 36.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 22,144 shares of the medical instruments supplier's stock valued at $1,638,000 after buying an additional 5,915 shares in the last quarter. Van ECK Associates Corp bought a new position in Merit Medical Systems in the third quarter valued at about $718,000. Lazard Asset Management LLC raised its position in Merit Medical Systems by 1,147.3% in the first quarter. Lazard Asset Management LLC now owns 7,858 shares of the medical instruments supplier's stock valued at $594,000 after purchasing an additional 7,228 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Merit Medical Systems by 2.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 838,843 shares of the medical instruments supplier's stock valued at $63,543,000 after purchasing an additional 22,077 shares during the last quarter. Finally, Natixis Advisors LLC raised its position in Merit Medical Systems by 10.8% in the second quarter. Natixis Advisors LLC now owns 66,535 shares of the medical instruments supplier's stock valued at $5,719,000 after purchasing an additional 6,487 shares during the last quarter. 99.66% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Merit Medical Systems

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 29,646 shares of the company's stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $98.02, for a total value of $2,905,900.92. Following the transaction, the chief financial officer now directly owns 16,361 shares of the company's stock, valued at $1,603,705.22. This represents a 64.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director F. Ann Millner sold 12,500 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.55, for a total value of $1,269,375.00. Following the sale, the director now directly owns 32,391 shares in the company, valued at approximately $3,289,306.05. This trade represents a 27.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is owned by company insiders.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.